Background TNBC is the most aggressive breast cancer with higher recurrence and
mortality rate than other types of breast cancer. There is an urgent need for identification of …

Gefitinib resistance in triple negative breast cancer (TNBC) is a growing important concern.
Glutathione peroxidase 4 (GPX4) is a main regulator of ferroptosis, which is pivotal for TNBC …

Abstract Targeting Glutathione peroxidase 4 (GPX4) has become a promising strategy for
drug-resistant cancer therapy via ferroptosis induction. It was found that the GPX4 inhibitors …

Abstract Glutathione peroxidase 4 (GPX4) has been confirmed to inhibit ferroptosis in cancer
cells, however, whether GPX4 serves as an oncogene is not clear. In this study, the …

Glutathione peroxidase 4 (GPX4) is an intracellular enzyme that oxidizes glutathione while
reducing lipid peroxides and is a promising target for cancer therapy. To date, several GPX4 …

Glutathione peroxidase 4 (GPX4) is a promising target to induce ferroptosis for the treatment
of triple-negative breast cancer (TNBC). We designed and synthesized a novel series of …

Cancer metabolic alterations have been emphasized to protect cancer cells from cell death.
The metabolic reprogramming toward a mesenchymal state makes cancer cells resistant to …

Ferroptosis is a new form of regulated cell death that is dependent on iron-and lipid reactive
oxygen species. Emerging evidence indicate that induction of ferroptosis could inhibit the …

Abstract Glutathione peroxidase 4 (GPx4) moonlights as structural protein and antioxidase
that powerfully inhibits lipid oxidation. In the past years, it is considered as a key regulator of …

Glutathione peroxidase 4 (GPX4) is one of the most important antioxidant enzymes. As the
key regulator of ferroptosis, GPX4 has attracted considerable attention in the fields of cancer …